Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials
Susannah G. Ellsworth; Timothée OlivierShow moreShow less
Department of Radiation Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA; Department of Medicine, University of Geneva (UNIGE), Geneva, Switzerland; Department of Oncology, Geneva University Hospital, Geneva, SwitzerlandShow moreShow less
Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial
Hyatt Balke-Want; Sebastian Theurich; Philipp Gödel; Stefanie Biedermann; Nicole Kreuzberg; Peter Borchmann; Danmei Zhang; Lena Weiss; Klara Dorman; Veit Bücklein; Marion Subklewe; Dirk Tomsitz; Lucie Heinzerling; Florentine Pia Altefrohne; Christine Schubert; Linda Hanssens; Liang Gao; Anders Wennborg; Heinz Haverkamp; Michael Apel; Tatjana Holzer; Ben Novak; Max Schlaak; Hinrich Abken; Nadine Kutsch; Michael von Bergwelt-BaildonShow moreShow less
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, University Hospital Cologne, Cologne, Germany; Cancer Center Cologne Essen (CCCE), Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Germany; Miltenyi Biotec, Bergisch Gladbach, Germany; Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Department of Dermatology and Allergology, LMU, Munich, Germany; Skin cancer center LMU, Munich, Germany; Miltenyi Biomedicine, Bergisch Gladbach, Germany; Department of Dermatology and Allergology, Vivantes Hospital Spandau, Berlin, Germany; Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, and Chair Genetic Immunotherapy, University Hospital Regensburg, GermanyShow moreShow less
Diagnostic challenges in WHO classification of thymic epithelial tumors: The clinical value of an international expert pathology panel
Marlou M. Dimmers; Daphne W. Dumoulin; Michael A. den Bakker; Anja C. Roden; Alexander Marx; Andre L. Moreira; Annika Weissferdt; Francien H. van Nederveen; Malgorzata Szolkowska; Nils A. ‘t Hart; Teodora Radonic; Thierry J. Molina; Wim Timens; Joachim G.J.V. Aerts; Jan H. von der ThüsenShow moreShow less
Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands; Department of Pathology, Maasstad Hospital, Rotterdam, the Netherlands; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; Department of Pathology, New York University Grossman School of Medicine, New York, USA; Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Pathology, Laboratory of Pathology Dordrecht, Dordrecht, the Netherlands; Department of Pathology, The Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; Department of Pathology, Isala, Zwolle, the Netherlands; Department of Pathology, Amsterdam University Medical Center & Cancer Center, Amsterdam, the Netherlands; Department of Pathology, Université Paris Cité, AP-HP, Hôpitaux Universitaires Robert Debré et Necker Enfants-Malades, France; Department of Pathology and Medical Biology, UMC Groningen, Groningen, the Netherlands; Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, the NetherlandsShow moreShow less
Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial
Nadine Kutsch; Hyatt Balke-Want; Stefanie Biedermann; Georg-Nikolaus Franke; Vladan Vučinić; Florentine Pia Altefrohne; Christine Schubert; Tobias Kampfenkel; Anders Wennborg; Heinz Haverkamp; Liang Gao; Tatjana Holzer; Ben Novak; Peter Borchmann; Philipp GödelShow moreShow less
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; Cancer Research Center Cologne Essen (CCCE), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany; Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, Hämostaseologie und Infektiologie, University Hospital Leipzig, Leipzig, Germany; Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany; Miltenyi Biomedicine GmbH, Bergisch Gladbach, GermanyShow moreShow less
Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions
Malek Shatila; David Farris; Pankti Reid; Thomas U. Marron; Sophia C. Weinmann; Alexa S. Meara; Yinghong WangShow moreShow less
Division of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, United States; Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Division of Rheumatology, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago Medical Center, Chicago, IL, United States; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Division of Rheumatology and Immunology, Duke University, Durham, NC, United States; Division of Rheumatology and Immunology, Ohio State University Wexner Medical Center, Columbus, OH, United States; Division of Gastroenterology and Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesShow moreShow less
What does addressing cancer inequalities really mean? Five principles that can drive global action
Matti Aapro; Nicolò Matteo Luca Battisti; Joseph Gligorov; Abiola Ibraheem; Dorothy Keefe; Stewart O’Callaghan; May Abdel-WahabShow moreShow less
Sharing Progress in Cancer Care, Bellinzona, Switzerland; Multidisciplinary Oncology Institute, Genolier, Switzerland; The Royal Marsden NHS Foundation Trust, Sutton, UK; Institute of Cancer Research, London, UK; European Cancer Organisation, Brussels, Belgium; Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Hospital Tenon Ap-Hp, Mediterranean Association for Radiotherapy Oncology and Medical Oncology (AROME), Paris, France; University of Illinois, Chicago, United States; African Organisation for Research and Training in Cancer (AORTIC), Chicago, United States; Cancer Australia, Sydney, Australia; College of Health, Adelaide University, Adelaide, Australia; OUTpatients LGBTIQ+ cancer charity, London, United Kingdom; Division of Human Health, Department of Nuclear Applications, International Atomic Energy Agency (IAEA), Vienna, AustriaShow moreShow less
FAQ
How long does EUROPEAN JOURNAL OF CANCER take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for EUROPEAN JOURNAL OF CANCER. The fastest paper went from submission to acceptance in 1 days (A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials, received 2026-10-15, accepted 2026-10-16); the slowest took 232 days. The average is 71.2 days and the median is 66.5 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
